East China Medicine: Exclusive commercial product application for market approval has been accepted by the National Medical Products Administration.

East China Pharmaceutical announced that on April 22, its wholly-owned subsidiary East China Pharmaceuticals Co., Ltd. has had its exclusive commercialized product CXG87 (capsule) drug registration and market approval application accepted by the National Medical Products Administration. This product is a 2.2-class improved new drug developed independently by Changxi Pharmaceutical, and is used to treat respiratory diseases such as asthma. The market approval application is based on positive results from Phase III clinical trials. If approved successfully, it is expected to benefit patients. However, uncertainties exist in drug evaluation and approval, as well as market competition, which may also impact the company's profits.